ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

QP. Quantum Phar.

84.2374
0.00 (0.00%)
08 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Quantum Phar. LSE:QP. London Ordinary Share GB00BRTL8Q42 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 84.2374 84.00 84.75 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Syquant Capital Form 8.3 - CLIN LN/QP LN (8518U)

27/10/2017 3:30pm

UK Regulatory


Quantum Phar. (LSE:QP.)
Historical Stock Chart


From Nov 2019 to Nov 2024

Click Here for more Quantum Phar. Charts.

TIDMCLIN TIDMQP.

RNS Number : 8518U

Syquant Capital

27 October 2017

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

   1.         KEY INFORMATION 
 
 (a) Identity of the person whose positions/dealings are being disclosed:                     SYQUANT CAPITAL 
-------------------------------------------------------------------------------------------  ------------------------- 
 (b) Owner or controller of interests and short positions disclosed, if different from 
 1(a): 
 The naming of nominee or vehicle companies is insufficient 
-------------------------------------------------------------------------------------------  ------------------------- 
 (c) Name of offeror/offeree in relation to whose relevant securities this form relates:      Clinigen Group plc 
  Use a separate form for each offeror/offeree 
-------------------------------------------------------------------------------------------  ------------------------- 
 (d) If an exempt fund manager connected with an offeror/offeree, state this and specify 
 identity 
 of offeror/offeree: 
-------------------------------------------------------------------------------------------  ------------------------- 
 (e) Date position held/dealing undertaken:                                                   26(th) October 2017 
-------------------------------------------------------------------------------------------  ------------------------- 
 (f) Has the discloser previously disclosed, or are they today disclosing, under the Code     YES - Quantum Pharma plc 
 in 
 respect of any other party to this offer? 
-------------------------------------------------------------------------------------------  ------------------------- 
 
   2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 
 Class of relevant security:                                    1p ordinary 
--------------------------------------------------  ---------------------------------- 
                                                       Interests      Short positions 
--------------------------------------------------  --------------  ------------------ 
                                                      Number    %     Number       % 
--------------------------------------------------  ---------  ---  ----------  ------ 
 (1) Relevant securities owned and/or controlled: 
--------------------------------------------------  ---------  ---  ----------  ------ 
 (2) Derivatives (other than options):                               115,087     0.09 
------------------------------------------------------------------  ----------  ------ 
 (3) Options and agreements to purchase/sell: 
--------------------------------------------------  ---------  ---  ----------  ------ 
 TOTAL:                                                              115,087     0.09 
------------------------------------------------------------------  ----------  ------ 
 

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other executive options)

 
 Class of relevant security in relation to which subscription right exists: 
---------------------------------------------------------------------------- 
 Details, including nature of the rights concerned and relevant percentages: 
---------------------------------------------------------------------------- 
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

   3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE 
   (a)        Purchases and sales 
 
 Class of relevant security   Purchase/sale   Number of securities   Price per unit 
---------------------------  --------------  ---------------------  --------------- 
 
 
   (b)        Derivatives transactions (other than options) 
 
    Class of relevant       Product description      Nature of dealing         Number of reference      Price per unit 
         security                 e.g. CFD         e.g. opening/closing a           securities 
                                                    long/short position, 
                                                   increasing/reducing a 
                                                    long/short position 
-------------------------  --------------------  -------------------------  -------------------------  --------------- 
                                                  increasing a short 
 0.1p ordinary              CFD                   position                                        162   1108 GBp 
-------------------------  --------------------  -------------------------  -------------------------  --------------- 
 
   (c)        Options transactions in respect of existing securities 
   (i)         Writing, selling, purchasing or varying 
 
   Class of       Product        Writing,      Number of       Exercise          Type       Expiry date   Option money 
   relevant     description    purchasing,     securities      price per         e.g.                        paid/ 
   security      e.g. call       selling,       to which         unit         American,                   received per 
                   option      varying etc.      option                        European                       unit 
                                                relates                          etc. 
-------------  -------------  -------------  -------------  --------------  -------------  ------------  ------------- 
 
 
   (ii)        Exercising 
 
 Class of relevant security   Product description   Number of securities   Exercise price per unit 
                                e.g. call option 
---------------------------  --------------------  ---------------------  ------------------------ 
 
 
   (d)        Other dealings (including subscribing for new securities) 
 
 Class of relevant security         Nature of dealing          Details   Price per unit (if applicable) 
                               e.g. subscription, conversion 
---------------------------  -------------------------------  --------  ------------------------------- 
 
 

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

   4.         OTHER INFORMATION 
   (a)        Indemnity and other dealing arrangements 
 
 Details of any indemnity or option arrangement, or any agreement or understanding, formal 
  or informal, relating to relevant securities which may be an inducement to deal or refrain 
  from dealing entered into by the person making the disclosure and any party to the offer or 
  any person acting in concert with a party to the offer: 
  If there are no such agreements, arrangements or understandings, state "none" 
--------------------------------------------------------------------------------------------- 
 
   N/A 
--------------------------------------------------------------------------------------------- 
 
   (b)        Agreements, arrangements or understandings relating to options or derivatives 
 
 Details of any agreement, arrangement or understanding, formal or informal, between the person 
  making the disclosure and any other person relating to: 
  (i) the voting rights of any relevant securities under any option; or 
  (ii) the voting rights or future acquisition or disposal of any relevant securities to which 
  any derivative is referenced: 
  If there are no such agreements, arrangements or understandings, state "none" 
----------------------------------------------------------------------------------------------- 
 
   N/A 
----------------------------------------------------------------------------------------------- 
 
   (c)        Attachments 
 
 Is a Supplemental Form 8 (Open Positions) attached?   NO 
----------------------------------------------------  --- 
 
 
 Date of disclosure:    27(th) October 2017 
---------------------  -------------------- 
 Contact name:          Laurent Boscherel 
---------------------  -------------------- 
 Telephone number:      +33 1 42 56 56 27 
---------------------  -------------------- 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RETEAEEXALDXFFF

(END) Dow Jones Newswires

October 27, 2017 10:30 ET (14:30 GMT)

1 Year Quantum Phar. Chart

1 Year Quantum Phar. Chart

1 Month Quantum Phar. Chart

1 Month Quantum Phar. Chart

Your Recent History

Delayed Upgrade Clock